Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.49 |
| ▸ | MAOA | P21397 | 6/20 | 0.45 |
| ▸ | CALML3 | P27482 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SDHA | P31040 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392369 | 0.92 | MAOB (0.49) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5381931 | 0.86 | MAOB (0.49) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5388137 | 0.85 | MAOB (0.51) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5404016 | 0.84 | MAOB (0.52) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5390489 | 0.84 | MAOB (0.50) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5385749 | 0.83 | MAOB (0.49) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5393418 | 0.83 | MAOB (0.46) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL7950997 | 0.83 | MAOB (0.65) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL7950993 | 0.83 | MAOB (0.65) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5391040 | 0.82 | MAOB (0.46) | MAOBMAOACALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040059120-A1 | Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2004-03-25 | — | — | US | claimed |
| US-7223758-B2 | Pyridazine derivative, pharmaceutical composition thereof, its pharmaceutical use, and process for its preparation | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| US-20050165017-A1 | Pyridazine derivative, pharmaceutical composition thereof, its pharmaceutical use, and process for its preparation | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | disclosed |
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION | 2003-04-03 | — | — | US | disclosed |
| US-4058662-A | Process for the substitution of chlorine atoms of cyanuric chloride | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065175-A1 | Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | MRPL21, Q6ZSR9, ZYX | MAOB 364/4885MAOA 460/4885CALML3 3452/4885 |
| US-20040059120-A1 | Novel heterocyclic compounds having antibacterial activity: Process for their preparation and pharmaceutical compositions containing them | MRPL21, Q6ZSR9, ZYX | MAOB 348/4885MAOA 456/4885CALML3 3458/4885 |
| US-20050165017-A1 | Pyridazine derivative, pharmaceutical composition thereof, its pharmaceutical use, and process for its preparation | CYP3A5, IL5, CYP2C19 | MAOB 202/4885MAOA 412/4885CALML3 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.